Mirum Pharmaceuticals, Inc. MIRM Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$23.36M+73.4% | -$87.94M+46.2% | -$163.42M-20.5% | -$135.67M— | ||
| $24.24M+2.6% | $23.63M+118% | $10.83M+234% | $3.24M+444% | ||
| $71.42M+47.4% | $48.44M+38.3% | $35.02M+29.7% | $27.01M+17.0% | ||
| $1.74M+4.7% | $1.66M+48.7% | $1.12M— | —— | ||
| $48.06M+321% | $11.43M-74.0% | $43.97M+112% | $20.73M— | ||
| $8.45M+167% | $3.17M— | —— | —— | ||
| —— | —— | $3.6M-2.1% | $3.68M-8.3% | ||
| $1.4M+76.2% | $795K-24.6% | $1.05M-70.0% | $3.51M— | ||
| -$1.9M-142% | -$782K+16.8% | -$940K-32.2% | -$711K-9.6% | ||
| $55.83M— | —— | -$70.94M+40.9% | -$120.14M+9.5% | ||
| $954K-3.9% | $993K— | —— | $278K+1,058% | ||
| $97.43M+9.4% | $89.03M— | —— | $132.32M-33.2% | ||
| $74.43M+274% | $19.89M-87.0% | $153M+9.1% | $140.3M-9.8% | ||
| $0-100% | $20M— | —— | —— | ||
| -$24.96M+72.5% | -$90.77M+15.3% | -$107.2M-1,492% | $7.7M-84.1% | ||
| $0— | $0— | —— | —— | ||
| $40.14M+127% | $17.7M-94.7% | $336.6M+208% | $109.42M+48.9% | ||
| —— | -$1.3M— | —— | $12K— | ||
| $75.24M+219% | -$63.4M— | —— | -$3.34M— | ||
| $2.16M+115% | $1M+703% | $125K— | $0— | ||
| $1.74M+4.7% | $1.66M+48.7% | $1.12M— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | $1.28M+180% | -$1.59M— | —— | ||
| $50.1M+24.3% | $40.31M+31.0% | $30.78M+303% | $7.64M— | ||
| —— | —— | —— | —— | ||
| -$1.9M-142% | -$782K+16.8% | -$940K-32.2% | -$711K-9.6% | ||
| $5.66M+278% | $1.5M— | —— | —— | ||
| —— | —— | $3.6M-2.1% | $3.68M-8.3% | ||
| —— | -$2.61M+71.8% | -$9.26M— | $0— | ||
| $1.73M+27.8% | $1.35M— | —— | —— | ||
| $1.4M+76.2% | $795K-24.6% | $1.05M-70.0% | $3.51M— | ||
| $0-100% | $20M— | —— | —— | ||
| $74.43M+274% | $19.89M-87.0% | $153M+9.1% | $140.3M-9.8% | ||
| —— | —— | $202.2M— | —— | ||
| $40.14M+127% | $17.7M+69.0% | $10.47M+44.0% | $7.27M+247% | ||
| $24K— | $0— | $0— | —— | ||
| —— | -$1.3M— | —— | $12K— | ||
| -$1.9M-142% | -$782K+16.8% | -$940K-32.2% | -$711K-9.6% | ||
| $2.59M+103% | $1.27M+18.1% | $1.08M+18.4% | $911K+5.4% | ||
| —— | —— | $0— | $0— | ||
| $2.44M— | —— | $473K— | —— | ||
| $688K-38.7% | $1.12M+36.5% | $822K+86.4% | $441K— | ||
| —— | —— | —— | —— | ||
| $2.16M+115% | $1M+703% | $125K— | $0— | ||
| $54.87M— | —— | -$71.05M+41.0% | -$120.41M+9.3% | ||
| $54.87M— | —— | -$71.05M+41.0% | -$120.41M+9.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Mirum Pharmaceuticals, Inc. generate?
- Mirum Pharmaceuticals, Inc. (MIRM) generated -$171.0M in operating cash flow over the trailing twelve months.
- What is Mirum Pharmaceuticals, Inc.'s free cash flow?
- After $1.6M of capital expenditures, Mirum Pharmaceuticals, Inc.'s free cash flow was -$172.6M over the trailing twelve months, down 45270.7% year over year.
- Where does Mirum Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
